Napier Financial’s Atossa Therapeutics ATOS Stock Holding History

Napier Financial’s Portfolio ATOS Stock Details ATOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$12	Hold	6	–	–	﹤0.01%	469
2026 Q1	$32	Buy	+6	New	+$38	﹤0.01%	603

Other funds holding ATOS

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Napier Financial's ATOS Position: Q2 2026 in Review

Napier Financial held its Atossa Therapeutics (ATOS) position steady in Q2 2026 at 6 shares worth $12. The position accounts for ﹤0.01% of the portfolio, ranked #469.

Napier Financial first reported a position in ATOS in Q1 2026 and has held it in 2 quarters since. The position peaked at $32 in Q1 2026. 31 funds tracked by Wall St. Rank hold ATOS as of Q2 2026.

Napier Financial held 6 shares of Atossa Therapeutics worth $12 as of Q2 2026.
Napier Financial left its Atossa Therapeutics share count unchanged in Q2 2026.
Atossa Therapeutics made up ﹤0.01% of Napier Financial's portfolio in Q2 2026, its #469 holding.
Napier Financial first reported a position in Atossa Therapeutics in Q1 2026 and has held it in 2 quarters since.
Napier Financial's Atossa Therapeutics position peaked at $32 in Q1 2026.
31 funds tracked by Wall St. Rank held Atossa Therapeutics as of Q2 2026.

Based on Napier Financial's 13F filing for Q2 2026, filed 31 Jul 2026.